Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

被引：0
|
作者：
Hassan Dorani
Kajs-Marie Schützer
Troy C. Sarich
Ulrika Wall
Ulrika Logren
Lis Ohlsson
Ulf G. Eriksson
机构：
[1] AstraZeneca Research and Development,Experimental Medicine
[2] AstraZeneca LP,undefined
[3] Johnson and Johnson Pharmaceutical Research and Development,undefined
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
Ximelagatran; Melagatran; Antibiotic interactions; Oral direct thrombin inhibitors; P-glycoprotein pump (p-GP);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 581
页数：10
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid
    Fager, G
    Cullberg, M
    Eriksson-Lepkowska, M
    Frison, L
    Eriksson, UG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (04) : 283 - 289
  • [22] No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
    Karin Wåhlander
    Maria Eriksson-Lepkowska
    Lars Frison
    Gunnar Fager
    Ulf G. Eriksson
    Clinical Pharmacokinetics, 2003, 42 (8) : 755 - 764
  • [23] Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
    Joachim Stangier
    Hildegard Stähle
    Karin Rathgen
    Reinhold Fuhr
    Clinical Pharmacokinetics, 2008, 47 : 47 - 59
  • [24] Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Stangier, Joachim
    Staehle, Hildegard
    Rathgen, Karin
    Fuhr, Reinhold
    CLINICAL PHARMACOKINETICS, 2008, 47 (01) : 47 - 59
  • [25] The effect of the oral direct thrombin inhibitor ximelagatran on the pharmacokinetics of P450-metabolized drugs, in healthy male volunteers.
    Eriksson-Lepkowska, M
    Thuresson, A
    Johansson, S
    Larsson, M
    Frison, L
    Bylock, A
    Eriksson, UG
    BLOOD, 2001, 98 (11) : 89B - 89B
  • [26] Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex)
    Koch, K
    Campanella, C
    Baidoo, CA
    Manzo, JA
    Ameen, VZ
    Kersey, KEE
    DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (7-8) : 1244 - 1249
  • [27] Pharmacodynamics and Pharmacokinetics of Oral Contraceptives Co-administered with Alosetron (Lotronex)
    Kevin Koch
    Corinne Campanella
    Charlotte A. Baidoo
    Janet A. Manzo
    Vanessa Z. Ameen
    Kathryn E. E. Kersey
    Digestive Diseases and Sciences, 2004, 49 : 1244 - 1249
  • [28] The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review
    Gustafsson, D
    Elg, M
    THROMBOSIS RESEARCH, 2003, 109 : S9 - S15
  • [29] Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran.
    Dorani, H
    Schützer, K
    Sarich, TC
    Wall, U
    Ohlsson, L
    Eriksson, UG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P78 - P78
  • [30] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
    Wolzt, M
    Wollbratt, M
    Svensson, M
    Wåhlander, K
    Grind, M
    Eriksson, UG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (07) : 537 - 543
12345